CTLA4 and small cell lung carcinoma: Several clinical trials have demonstrated the persistent efcacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC.